Artemisinin-based combination therapy for ... - The Cochrane Library

Falade 2005 NGA (Continued)
Camoquine: Pfizer)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
All doses supervized and given with food, fruit drink, or dissolved in water
Outcomes 1. ACPR at day 28, PCR adjusted and unadjusted
2. Haematocrit on days 0, 7, and 28
3. Adverse events, including mean WBC and liver enzymes
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Nigeria
Setting: General Outpatient Department of University College Hospital
Transmission: Intense and occurs all year round
Resistance: CQ and SP
Dates: Aug 2004 to Aug 2005
Funding: Study meds were supplied by Novartis, Sanofi-Sycitilabo and Pfizer
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’A pregenerated randomisation table’
Allocation concealment? No None described
Blinding?
All outcomes
Incomplete outcome data addressed?
All outcomes
No An open label trial. No comment on blinding
of lab staff
Yes Low losses to follow up in both groups
(7.5% AL6 vs 6.0% AS+AQ)
Free of selective reporting? Yes All WHO outcomes reported. The WHO
recommends 42 days follow up in studies of
AL6. Day 28 outcomes may under estimate
treatment failure with AL6.
Free of other bias? Yes No other sources of bias identified
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
52